- Record: found
- Abstract: not found
- Article: not found
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
John R. Teerlink
1 ,
Rafael Diaz
1 ,
G. Michael Felker
1 ,
John J.V. McMurray
1 ,
Marco Metra
1 ,
Scott D. Solomon
1 ,
Kirkwood F. Adams
1 ,
Inder Anand
1 ,
Alexandra Arias-Mendoza
1 ,
Tor Biering-Sørensen
1 ,
Michael Böhm
1 ,
Diana Bonderman
1 ,
John G.F. Cleland
1 ,
Ramon Corbalan
1 ,
Maria G. Crespo-Leiro
1 ,
Ulf Dahlström
1 ,
Luis E. Echeverria
1 ,
James C. Fang
1 ,
Gerasimos Filippatos
1 ,
Cândida Fonseca
1 ,
Eva Goncalvesova
1 ,
Assen R. Goudev
1 ,
Jonathan G. Howlett
1 ,
David E. Lanfear
1 ,
Jing Li
1 ,
Mayanna Lund
1 ,
Peter Macdonald
1 ,
Viacheslav Mareev
1 ,
Shin-ichi Momomura
1 ,
Eileen O’Meara
1 ,
Alexander Parkhomenko
1 ,
Piotr Ponikowski
1 ,
Felix J.A. Ramires
1 ,
Pranas Serpytis
1 ,
Karen Sliwa
1 ,
Jindrich Spinar
1 ,
Thomas M. Suter
1 ,
Janos Tomcsanyi
1 ,
Hans Vandekerckhove
1 ,
Dragos Vinereanu
1 ,
Adriaan A. Voors
1 ,
Mehmet B. Yilmaz
1 ,
Faiez Zannad
1 ,
Lucie Sharpsten
1 ,
Jason C. Legg
1 ,
Claire Varin
1 ,
Narimon Honarpour
1 ,
Siddique A. Abbasi
1 ,
Fady I. Malik
1 ,
Christopher E. Kurtz
1
November 13 2020
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d5432971e455">The selective cardiac myosin activator omecamtiv
mecarbil has been shown to improve
cardiac function in patients with heart failure with a reduced ejection fraction.
Its effect on cardiovascular outcomes is unknown.
</p>